Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
AACR 2025 preview – a surge in dual-payload conjugates
No fewer than 14 dual-payload ADCs will be discussed.
MacroGenics cuts down its Tamarack
Vobra-duo is discontinued at long last.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
